Paradigm Health Secures $78M Series B Led by ARCH Venture Partners

Why It Matters

The infusion accelerates Paradigm's ability to modernize trial operations, potentially reducing costs and timelines while strengthening its position in the expanding health‑tech infrastructure market.

Key Takeaways

• $78M Series B led by ARCH Venture Partners
• New investor DFJ Growth joins existing backers
• Funding targets platform scaling and AI analytics
• Aims to streamline clinical trial data workflows
• Highlights rising investor interest in health‑tech infrastructure

Pulse Analysis

Paradigm Health has emerged as a pivotal technology platform for the clinical research ecosystem, offering end‑to‑end data management, patient recruitment, and AI‑driven analytics. Based in Columbus, Ohio, the company leverages cloud infrastructure to connect sponsors, sites, and investigators, reducing friction that traditionally slows trial execution. As pharmaceutical firms accelerate pipelines and regulators push for faster approvals, demand for digital solutions that improve trial efficiency has surged, positioning firms like Paradigm at the forefront of a multi‑billion‑dollar market.

The latest $78 million Series B round, led by ARCH Venture Partners and joined by DFJ Growth, underscores strong venture confidence in Paradigm’s growth trajectory. Existing backers—including F‑Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and the American Cancer Society’s BrightEdge Fund—reinforced their commitment, signaling validation of the company’s technology stack and customer traction. The capital will fund platform scaling, integration of advanced machine‑learning models, and expansion into new therapeutic areas, while also supporting strategic hires in sales and regulatory affairs.

With this infusion, Paradigm is poised to accelerate the digital transformation of clinical trials, potentially shaving months off study timelines and lowering operational costs for sponsors. The move also reflects a broader investor shift toward infrastructure‑level health‑tech, where data interoperability and real‑time analytics are becoming critical differentiators. As the industry grapples with patient recruitment challenges and the need for decentralized trial models, Paradigm’s expanded capabilities could set new standards for speed, transparency, and outcome predictability.

Deal Summary

Paradigm Health, a Columbus‑based health‑tech firm, announced a $78 million Series B round led by ARCH Venture Partners, with participation from DFJ Growth and several existing backers. The capital will fuel the expansion of its clinical‑research platform and broader growth initiatives.